α干扰素（IFN-α）联合利巴韦林是目前临床治疗丙型肝炎病毒（HCV）感染的标准方案。本研究以体外培养的感染性病毒HCVcc为研究对象，比较IFN-α和利巴韦林对HCV复制的影响以及对干扰素调节因子9（IRF9）和干扰素刺激基因15（ISG15）等抗病毒基因的调节能力。结果显示，100 u/ml IFN-α显著降低HCV RNA水平；利巴韦林剂量依赖性抑制HCV复制，且IFN-α联合利巴韦林对HCV复制及HCV NS3和E2蛋白表达具有协同抑制作用。5~80 u/ml IFN-α剂量依赖性诱生IRF9和ISG15；1、5 μg/ml利巴韦林不促进IRF9和ISG15水平升高，而利巴韦林联合IFN-α对两者亦无促进作用。

The current standard therapy for hepatitis C virus (HCV) infection consists of a combination of interferon α(IFN-α) and ribavirin. In this study, the effects of IFN-α and ribavirin on HCV replication as well as antiviral genes were examined. The results showed that 100 u/ml IFN-α significantly reduced HCV RNA levels. Ribavirin inhibited HCV replication in a dose-dependent manner and ribavirin in combination with IFN-α exhibited synergetic inhibitory effect on HCV replication, and NS3 and E2 protein expression. IFN-α increased the levels of IFN regulatory factor 9 (IRF9) and IFN-stimulated gene 15 (ISG15) in a dose-dependent manner. However, 1 and 5 μg/ml ribavirin had no such effects on the IRF9 and ISG15 induction.